logo
Unily Appoints Lokdeep Singh as Chief Executive Officer

Unily Appoints Lokdeep Singh as Chief Executive Officer

Associated Press19 hours ago

Unily appoints Lokdeep Singh as Chief Executive Officer, signaling the next phase of growth for the leading Employee Experience Platform provider.
LONDON, UNITED KINGDOM, June 13, 2025 / EINPresswire.com / -- Unily, the award-winning Employee Experience Platform powering the world's most iconic enterprises, today announced the appointment of Lokdeep Singh as Chief Executive Officer, effective immediately. The appointment comes at a time of accelerating growth and innovation for the company, as it continues to lead the market in transforming the way organizations connect, engage, and empower their people.
'I am honored to join Unily as CEO,' said Singh. 'I have an immense amount of respect for the company's vision, culture, and platform. Unily is uniquely positioned to help organizations thrive in a world where agility and alignment are more critical than ever. I look forward to working closely with the talented team at Unily to further scale the business, deliver exceptional value to our customers, and fuel the next chapter of growth.'
Singh is a seasoned technology executive with more than two decades of experience in leading high-growth enterprise software companies. Most recently, Singh served as a Senior Advisor at Providence Equity Partners, where he supported portfolio companies on AI strategy, operational excellence, and go-to-market acceleration. Prior to that, Singh was CEO of Talkwalker, a global leader in enterprise consumer intelligence, where he led the company through a transformative growth period culminating in a successful acquisition in 2024.
'Lokdeep brings a rare combination of strategic vision, operational rigor, and deep understanding of enterprise needs,' said Will Saville, Unily Co-Founder and Board Member. 'His leadership comes at a pivotal time for Unily, as we double down on innovation, scale our global footprint, and continue to lead the category we created. We're thrilled to welcome him aboard.'
Singh joins Unily as the company is experiencing strong momentum:
· Recently recognized as a Leader by Gartner, Forrester, and IDC in the Employee Experience Platform category;
· Trusted by global enterprises such as Shell, CVS Health, British Airways, and Wipro;
· Investing heavily in AI-driven capabilities to redefine productivity and employee engagement;
· And expanding its partner ecosystem and global presence to support growing international demand.
'Our customers are looking for strategic partners who can help them simplify complexity and move faster,' Singh added. 'Unily is that partner. I'm excited to help accelerate this mission with bold innovation and deep customer focus.'
About Unily
Unily is the only true enterprise Employee Experience Platform, driving organizational velocity for the world's most iconic brands. In today's fast-changing world, Unily helps industry leaders like Shell, CVS Health, and American Airlines move faster, align teams, and drive execution excellence. As the only company in the industry recognized as a Leader by Gartner, Forrester, and IDC, Unily is redefining the future of work – empowering enterprises to eliminate friction and operate at the speed of success.
Casey Farr
5WPR
+44 7717 575414
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch
Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch

Yahoo

time2 hours ago

  • Yahoo

Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch

Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies have raised the price target for Verona Pharma plc (NASDAQ:VRNA) to $110, up from $95, with an unchanged 'Buy' rating. This was after the successful launch of the COPD treatment Ohtuvayre, which has witnessed strong sales growth. During the first quarter, Ohtuvayre delivered $71 million in sales, reflecting an increase of nearly 90% from the previously reported 37 million in the last quarter. Verona Pharma plc (NASDAQ:VRNA) continues to capitalize on this growing demand, with peak sales projections between $3 billion and $5 billion. As the numbers suggest, this is anything but ordinary. The optimism surrounding the company's profitability in the second quarter is just the cherry on top. A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Some believe that Verona Pharma plc (NASDAQ:VRNA) is heading north to be the next big franchise. With its potential, Wall Street anticipates the giant to achieve $1 billion in sales by 2028, driven by its safety profile, global expansion, robust patent protection, and an underserved market of 398 million people with COPD. Verona Pharma plc (NASDAQ:VRNA) is a London-based biopharmaceutical company that develops and markets therapies for treating patients suffering from respiratory diseases. Incorporated in 2005, the company is committed to improving the lives of many by offering innovative drugs. While we acknowledge the potential of VRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch
Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch

Yahoo

time2 hours ago

  • Yahoo

Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch

Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies have raised the price target for Verona Pharma plc (NASDAQ:VRNA) to $110, up from $95, with an unchanged 'Buy' rating. This was after the successful launch of the COPD treatment Ohtuvayre, which has witnessed strong sales growth. During the first quarter, Ohtuvayre delivered $71 million in sales, reflecting an increase of nearly 90% from the previously reported 37 million in the last quarter. Verona Pharma plc (NASDAQ:VRNA) continues to capitalize on this growing demand, with peak sales projections between $3 billion and $5 billion. As the numbers suggest, this is anything but ordinary. The optimism surrounding the company's profitability in the second quarter is just the cherry on top. A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Some believe that Verona Pharma plc (NASDAQ:VRNA) is heading north to be the next big franchise. With its potential, Wall Street anticipates the giant to achieve $1 billion in sales by 2028, driven by its safety profile, global expansion, robust patent protection, and an underserved market of 398 million people with COPD. Verona Pharma plc (NASDAQ:VRNA) is a London-based biopharmaceutical company that develops and markets therapies for treating patients suffering from respiratory diseases. Incorporated in 2005, the company is committed to improving the lives of many by offering innovative drugs. While we acknowledge the potential of VRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store